Expert John Streicher, PhD Professor, Department of Pharmacology, College of Medicine Tucson Member, Comprehensive Center for Pain & Addiction, U of A Health Sciences Contact Phil Villarreal U of A Health Sciences Office of Communications 520-403-1986, [email protected]
Written By: Pharmacally Medical News Desk AstraZenecas investigational oral GLP1 receptor agonist elecoglipron (AZD5004) is advancing toward Phase III development, supported by positive Phase IIb data in both type 2 diabetes and chronic weight management as outlined in the companys FY 2025 Clinical Trials Appendix
Additionally, GLP-1s can function as appetite suppressants, helping regulate appetite but potentially making it difficult to tell when youre hungry or need to eat (3)
doi:10.1177/21501319221081277
In these situations, B12 injections at Lifeline Primary Care can make a real difference, improving your energy levels and addressing the underlying deficiency
Weight loss and reduced food intake make zinc deficiency more likely
